Pharmacogenetic Variation: Factors That May Affect the Efficacy and Safety of Medical Marijuana
Completed · NCT04083261
Conditions: New York Medical Marijuana Program Qualifying Conditions
At a glance
- Research payments reported, 2025
- $2,062
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 157
About the trial
- Sponsor
- Columbia Care Inc.
- Tested
- DNA Genotek Oragene 600 (other)
- Dates
- Started 2019-07-11; completion 2020-03-30
- Results posted
- Not yet
The primary purpose of this research is to identify genetic factors that may affect the efficacy and safety of medical marijuana, regardless of condition. The pharmacogenomics test detects DNA variants, which may affect the way drugs work and are metabolized in the body and/or detect potential side effects.
From ClinicalTrials.gov, last updated 2020-07-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Bioscience Inc. reported $2,062 in research payments for this study in 2025 (1 payments).
Products named: Onivyde
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $2,062
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.